20% Albumin vs. Balanced Salt Solution as Resuscitation Fluid in Cirrhosis With Sepsis Induced Hypotension
Key facts
- Who runs it
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Where
- India1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 4
- People taking part
- 150 people, planned
- Started
- 15 Aug 2020
- Expected to end
- Dec 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- 20% albumin
- Balanced salt solution
- Record updated
- 13 November 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (15)Hide the full registry criteria
Who can take part
- Clinical/Imaging or Biopsy proven liver cirrhosis of any etiology who consent for enrolment
- Hypotension (Mean arterial pressure <65mmHg or Systolic blood pressure <90mmHg)
- Aged between18-65 yrs
Who cannot take part
- Already received colloid or more than 2 litres of fluid without baseline echocardiographic assessment
- Severe pre-existing cardiopulmonary disease
- Acute Respiratory Distress Syndrome (ARDS)
- Active bleeding like variceal bleed
- Chronic renal disease - End Stage Renal Disease (ESRD)/ patient on renal replacement therapy
- Admission to ICU following liver transplantation, burns, cardiac surgery
- Previous adverse reaction to human albumin solution
- Already on vasopressors/inotropes
- Cerebrovascular events
- Brain death or likely brain death within 24 hours
- Pregnant or lactating women
- Informed consent refused by patient or attendants
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Patients with cirrhosis patients have a high incidence of sepsis which can trigger decompensation and may result in prolonged hospital stay and increased mortality. About 30%-50% admissions of patients with cirrhosis have sepsis at presentation and about 15% patients admitted to hospital develop sepsis during the hospital stay . After infection develops, the patient may develop acute kidney injury (AKI), shock, encephalopathy or disseminated intravascular coagulation (DIC) further decreasing the chances of survival. In fact, sepsis in patients with cirrhosis is associated with 15% in-hospital mortality, approximately double that of patients without sepsis. So, sepsis is directly responsible for 30-50% of deaths in cirrhosis . Therefore, it is critical to manage sepsis early and appropriately in cirrhosis to reduce the complications and mortality. Early administration of fluids, source control and empirical antibiotics along with vasopressors if refractory shock are essential components of treatment in all patients with sepsis. Currently, the most accepted strategy for early sepsis management is a combination of early goal directed therapy (EGDT) and physiological parameters, such as urine output, lactate clearance, and administration of antibiotics, within 1 hour of presentation . The use of central venous pressure assessment is fallacious for gauging adequacy of fluid resuscitation in cirrhosis, and the difficulty of performing echocardiographic assessments in the setting of ascites and cirrhotic cardiomyopathy is also well described .
The 2 groups in the trial
- 20% Albumin armTreatment being tested
20% Albumin in a dose of 20-40 gm per day as infusion over 12-24 h
Treatment: 20% albumin and Balanced salt solution
- Balanced salt solution armExisting treatment, for comparison
Fluid resuscitation protocol includes use of an immediate 500 ml bolus of crystalloid i.e., balanced salt solution (BSS) or 0.9% normal saline (Rescue phase), followed by 20 ml/kg fluid in the first 6 hours titrated to target MAP of \> 65mmHg.The second phase of fluid resuscitation (Optimization phase) will be performed as per IVC targets, attainment of lactate clearance, and LUS score to prevent overload.
Treatment: Balanced salt solution
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- To Compare 20% Albumin vs. Balanced Salt Solution as Resuscitation Fluid and Identify Fluid Responsiveness Criteria in Critically Ill Patients With Cirrhosis With Sepsis Induced Hypotension; a Prospective Randomized Controlled Trial.
- Record updated
- 13 November 2026